Medical Condition News

RSS

Perrigo files NDA with FDA for generic Zegerid OTC

Perrigo Company announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) for omeprazole 20mg/sodium bicarbonate 1100mg, the generic equivalent of Zegerid OTC™, and that it provided prior notice of this filing to Schering-Plough HealthCare Products, Inc. a subsidiary of Merck & Co., Inc., the owner of the brand regulatory approval and the Curators of the University of Missouri, the listed patent owner.

24 Sep 2010

Results of Argos' Arcelis Phase 2 study for RCC accepted for presentation at International Kidney Cancer Symposium

Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.

24 Sep 2010

Yaupon reports positive results from mechlorethamine gel study for early-stage cutaneous T-cell lymphoma

Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.

24 Sep 2010

Cylene commences CX-4945 Phase I trial in multiple myeloma

Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma. Cylene also announced the simultaneous closing of a $12 million financing with participation from existing investors including Sanderling Ventures, HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments Ltd.

24 Sep 2010

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

OrbusNeich today announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington the completion of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) with 183 patients included at sites in Asia, Australia, Europe and South America.

24 Sep 2010

Parents and coaches should be mindful of risks of concussions

With the recent deaths of football players top of mind, parents and coaches should always be mindful of the risks of concussions. Kim Gorgens, assistant professor and neuropsychologist at the University of Denver (DU), says that the average football player receives 103 Gs when hit during a game. Most concussions deliver 95 Gs to the human body upon impact.

24 Sep 2010

NYU Langone Medical Center announces presentations at TCT 2010 scientific symposium

Researchers from the Cardiac & Vascular Institute at NYU Langone Medical Center will present at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium on September 21-25, 2010 in Washington, DC.

24 Sep 2010

MTHFD1L gene may increase risk of developing late-onset Alzheimer's disease

Researchers have identified a gene that appears to increase a person's risk of developing late-onset Alzheimer's disease, the most common form of the disease. The gene, abbreviated as MTHFD1L, is on chromosome six, and was identified in a genome-wide association study.

24 Sep 2010

Yoga, Tai Chi effective in treating fibromyalgia

This syndrome is often accompanied by fatigue, bowel disturbances, and urinary difficulty. Fibromyalgia can affect your daily activity, your sleep, and even your thinking when you're worn out and experiencing "brain fog." That's a term used by Henri Roca, MD, Medical Director at Greenwich Hospital's Center for Integrative Medicine in Cos Cob, Connecticut.

24 Sep 2010

Phase 3 clinical study demonstrates efficacy of metformin therapy in type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes inadequately controlled on metformin therapy alone.

24 Sep 2010

HIV-infected African Americans likely to develop kidney failure: Study

Among African Americans, HIV infection is increasingly recognized as an important risk factor for developing chronic kidney disease. African American men and women are more likely to die from the complications of HIV infection compared with Caucasian men and women.

24 Sep 2010

Disenrollment from hospice increases costs of care for cancer patients

Researchers at Mount Sinai School of Medicine have found that the costs of care for patients with cancer who disenrolled from hospice were nearly five times higher than for patients who remained with hospice. Patients who disenroll from hospice are far more likely to use emergency department care and be hospitalized. The results are published in the October 1 issue of the Journal of Clinical Oncology.

24 Sep 2010

Researchers discover new signaling pathway for cell development

Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a new cell signaling pathway that controls cell growth and development, a pathway that, when defective, helps promote the formation of several major forms of human cancer, including lymphoma and leukemia.

24 Sep 2010

Malnutrition, inflammation complicate blood cholesterol readings in CKD patients

To understand the health effects of high cholesterol levels, doctors first need to assess malnutrition and inflammation status in their chronic kidney disease (CKD) patients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

24 Sep 2010

Study: PTNS offers an effective treatment option for detrusor overactivity incontinence

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results of a study "Percutaneous Tibial Nerve Stimulation Effects on Detrusor Overactivity Incontinence Are Not Due to a Placebo Effect A Randomized, Double-Blind, Placebo Controlled Trial," to be published in the November 2010 print edition of THE JOURNAL OF UROLOGY.

24 Sep 2010

Preclinical data of novel drug-resistant hypertension therapy presented at TCT 2010

Preclinical data of a novel therapy designed to treat drug-resistant hypertension (high blood pressure) was presented Tuesday, September 21st, at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 Conference in Washington, DC, by Christopher D. Owens, MD, MSc, Assistant Professor in Residence, Division of Vascular and Endovascular Surgery, University of California, San Francisco.

24 Sep 2010

UC San Diego receives grant to study hypoxia susceptibility

Gabriel G. Haddad, MD, chair of the Department of Pediatrics at the University of California, San Diego School of Medicine and Physician-in-Chief at Rady Children's Hospital-San Diego has received a $10 million grant from the National Institute of Health's Heart, Lung and Blood Institute.

24 Sep 2010

Scientists uncover alternative source for damage associated with MS

Scientists have uncovered an alternative source for some of the damage associated with multiple sclerosis, an incurable neuroinflammatory disorder. The research, published online by Cell Press on September 23rd in the journal Immunity, reveals a direct interaction between immune cells and neurons that plays a significant role in neuronal injury and may respond to therapeutic intervention.

24 Sep 2010

Increased awareness, improved treatments not mammograms responsible for drop in breast cancer deaths, Study finds

A new study suggests that increased awareness and improved treatments rather than mammograms are the main force in reducing the breast cancer death rate.

24 Sep 2010

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Following today’s announcements by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for rosiglitazone in the U.S. and Europe, Takeda Pharmaceuticals North America, Inc. and Takeda Pharmaceuticals Europe Limited underscore the company’s commitment to ACTOS® (pioglitazone HCl) and ACTOS-containing medications, and to the millions of people living with type 2 diabetes.

24 Sep 2010

Medical Condition News

Perrigo files NDA with FDA for generic Zegerid OTC

Results of Argos' Arcelis Phase 2 study for RCC accepted for presentation at International Kidney Cancer Symposium

Yaupon reports positive results from mechlorethamine gel study for early-stage cutaneous T-cell lymphoma

Cylene commences CX-4945 Phase I trial in multiple myeloma

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

Parents and coaches should be mindful of risks of concussions

NYU Langone Medical Center announces presentations at TCT 2010 scientific symposium

MTHFD1L gene may increase risk of developing late-onset Alzheimer's disease

Yoga, Tai Chi effective in treating fibromyalgia

Phase 3 clinical study demonstrates efficacy of metformin therapy in type 2 diabetes

HIV-infected African Americans likely to develop kidney failure: Study

Disenrollment from hospice increases costs of care for cancer patients

Researchers discover new signaling pathway for cell development

Malnutrition, inflammation complicate blood cholesterol readings in CKD patients

Study: PTNS offers an effective treatment option for detrusor overactivity incontinence

Preclinical data of novel drug-resistant hypertension therapy presented at TCT 2010

UC San Diego receives grant to study hypoxia susceptibility

Scientists uncover alternative source for damage associated with MS

Increased awareness, improved treatments not mammograms responsible for drop in breast cancer deaths, Study finds

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News